H ypoxic regions are characteristic of solid tumors in rodents 1 and occur with high frequency in many types of human tumors. 2 Tissue oxygen electrode measurements taken in cancer patients show a median range of oxygen partial pressure of 10 -30 mmHg in tumors, with a significant proportion of readings below 2.5 mmHg, whereas those in normal tissues range from 24 to 66 mmHg. 3 Gene therapy in solid tumors that targets gene expression to hypoxic tumor cells is currently being investigated. 4 It is known that certain species of anaerobic bacteria, including the genera Clostridium and Bifidobacterium, can selectively germinate and grow in the hypoxic regions of solid tumors after intravenous (i.v.) injection. 5, 6 The genera Bifidobacterium and Lactobacillus are Grampositive anaerobes and are domestic, nonpathogenic bacteria found in the lower small intestine and large intestine of humans and other animals. [7] [8] [9] These intestinal organisms have been believed to have health-promoting properties for their host, including an increase of the immune response, 10 inhibition of carcinogenesis, 11 and protection of the host against viral infection.
12
However, despite the increasing attention to these bacteria in the fields of food science, medicine, and industry, little is known about their genetic properties, mainly due to the lack of efficient and reproducible systems for genetic transfer and adequate selectable markers, especially with regard to the genus Bifidobacterium. Recently, an Escherichia coli-B. longum shuttle vector has been constructed. 13 We propose an innovative approach to cancer gene therapy in which genetically engineered anaerobic bacteria of the genus Bifidobacterium are used to achieve tumor-specific gene delivery.
MATERIALS AND METHODS

Animals
Male C57BL/6 mice (Japan SLC, Hamamatsu, Japan) of 6 to 8 weeks of age were used in this study. Mice were fed a standard rodent diet (Oriental Yeast Company, Tokyo, Japan) in the Shinshu University animal center.
Tumors
B16-F10 melanoma cells and Lewis lung cancer cells were maintained as monolayer cultures in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37°C in an atmosphere of 5% CO 2 . A total of 5 ϫ 10 5 tumor cells were inoculated into the right thigh muscle of these mice. The solid tumors obtained 2 weeks after inoculation were then used for study.
Bacteria
B. longum 105-A and 108-A were anaerobically cultured at 37°C to middle log phase in slightly modified Briggs broth, 14, 15 with glucose replaced by 2% lactose. The original B. longum was diluted 10-fold with phosphate-buffered saline (PBS) (pH 7.4); a total of 0.5 mL of the diluted suspension was then injected into the tumor-bearing mice via the tail vein. Immediately after injections, the suspension was quantitatively diluted and cultured as described below to determine the actual number of viable bacilli contained in the inoculum; this number was generally 5-6 ϫ 10 6 bacilli/mouse.
Treatment of mice with lactulose
Lactulose was kindly provided by Nikken Chemicals (Tokyo, Japan) and was used as a 20% water solution after sterilization.
As preliminary experiments, Lewis lung cancer tumor-bearing mice were given in a single i.v. injection of B. longum 9 days previously, followed by daily intraperitoneal (i.p.) administrations of 1 mL of 20% lactulose solution or 1 mL of PBS; the number of bacilli per gram of tumor tissues of the animals given lactulose was ϳ200-fold more than that of the mice treated with PBS (data not shown). The bacterial suspension was administered i.v. to the mice on day 0, and thereafter 1 mL of 20% lactulose was administered i.p. daily starting from day 0 to the day of sacrifice.
Preparation of tissue homogenate
At 1, 24, 48, 72, 96, and 168 hours (7 days) after injection of the B. longum (i.v.) and lactulose (i.p.) solutions as described above, six to eight tumor-bearing mice were sacrificed. Normal tissue samples that had been obtained from the lung, liver, spleen, kidney, and heart were used. These normal tissues and the whole tumor, which grew at the right thigh, were excised and minced thoroughly, and a sample was weighed and placed in a homogenizer to prepare a 10% homogenate with cold PBS under aseptic conditions.
Culture condition
Refrigerated, solidified culture medium (1.5% Briggs agar) was melted in boiling water, and L-cysteine and sodium ascorbate (20 mg/mL and 340 mg/mL final concentration, respectively) were added to the medium when the temperature dropped to Ͻ55°C. Thereafter, the medium was kept in a 55°C water bath ready for use. The diluted tissue homogenate, 100 L (ϭ 0.01 g)/dish, was inoculated into two dishes per sample and thoroughly mixed with the medium. After the agar medium was solidified at room temperature, all dishes were placed in a completely airtight desiccator at 37°C under anaerobic conditions. On day 3 of culture, the number of colonies per dish was determined. 
Plasmid construction and transformation of B. longum
A shuttle vector, pBLES100, was constructed by cloning a B. longum plasmid and a gene encoding spectinomycin adenyltransferase AAD(9) from Enterococcus faecalis into the E. coli vector pBR322. Full details of the plasmid construction are presented elsewhere. 13 The pBLES100 constructs were transferred directly into B. longum 105-A or 108-A by electroporation. Stable transformants were obtained with an efficiency of 1.6 ϫ 10 4 and 2.6 ϫ 10 3 transformants/g DNA under the optimum conditions, using B. longum 105-A and 108-A, respectively. Transformed B. longum was grown under anaerobic conditions at 37°C in Briggs broth containing 75 g/mL spectinomycin. These bacilli were injected i.v. into tumorbearing mice as described above. 
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Animals were sacrificed at 168 hours after bacterium injection. Tumors and normal tissues were then excised, fixed in 10% formalin solution, sectioned in paraffin, and stained with a Gram's stain.
Spectinomycin-resistant gene delivery into the hypoxic tumors
The mice bearing a B16-F10 melanoma with administration of transformed B. longum 105-A with spectinomycin-resistant gene were divided into two groups: (a) four mice to which spectinomycin (200 mg/kg) was administered i.p. daily starting from day 1 to day 3 and sacrificed on day 4; (b) as a control, four mice were given PBS instead of spectinomycin. The mice with administration of wild-type (wt) B. longum 105-A were also divided; four mice each were placed in the spectinomycin and control groups. Tumors of each group were excised and cultured without the spectinomycin conditions. For statistical analysis, the Mann-Whitney U test (Statview-J4.11, Abacus Concepts, Berkeley, Calif) was used to compare the number of bacilli between treatment groups receiving spectinomycin or PBS. A P value of Ͻ.01 was considered significant. Figure 1 shows the number of B. longum 105-A and 108-A organisms per gram of various tissues at various time intervals after i.v. administration of 5-6 ϫ 10 6 viable bacilli into mice bearing Lewis lung cancer tumors. At 168 hours, tumors had ϳ60,000 bacilli per gram of tumor tissue regardless of the bacterial strain used. In contrast, the number of B. longum organisms in nonmalignant tissues, such as the liver, spleen, kidney, and lung from the tumor-bearing mice, began to decrease immediately after injection. Bacilli were below detectable levels in all normal tissues after 168 hours with B. longum 105-A and after 96 hours with B. longum 108-A. We examined the number of B. longum 108-A per gram of various tissues at 96 hours after i.v. administration of 5-6 ϫ 10 6 viable bacilli into B16-F10 melanoma tumorbearing mice. Bacilli were detected in the tumor tissue only but not in normal livers, spleens, kidneys, or lungs (data not shown).
RESULTS
Selective growth of unmodified B. longum in tumor tissues
Histology
Lewis lung cancer tumor-bearing mice were injected i.v. with wt B. longum, killed 168 hours later, and examined for the presence of Gram-positive bifidobacterial rods in both tumors and normal tissues. Numerous bacilli were scattered in the necrotic region of the tumor. Gram's staining of histological sections indicated that B. longum did not germinate in normal tissues, including the lung, liver, spleen, kidney, and heart (Fig 2, A-C) .
Selective growth of genetically engineered B. longum in tumor tissues
The wt B. longum strain 105-A was transfected with plasmid pBLES100. Both Lewis lung cancer and B16-F10 melanoma tumor-bearing mice were injected i.v. with 5-6 ϫ 10 6 viable pBLES100-carrying B. longum 105-A, killed 168 hours later, and examined for the presence of bacilli in both tumors and several normal tissues. The number of the transformed B. longum 105-A per gram of various tissues of the two kinds of tumorbearing mice are shown in Figure 3 . Both Lewis lung cancer tumors and B16-F10 melanoma tumors exhibited a heavy infestation of bacilli as well as wt. However, in the normal tissues such as the lung, liver, spleen, and kidney, no bacilli were detected. As shown in Figure 4 , ϳ400 colonies were recognized on the spectinomycincontaining agar plate; these colonies inoculated the tumor tissue only. Figure 5 shows the number of wt B. longum 105-A and transformed B. longum per gram of tumor tissue of mice bearing a B16-F10 melanoma. When spectinomycin was given to the animals injected with wt B. longum 105-A, the number of bacilli significantly decreased compared with the control group treated with PBS (P Ͻ .01). However, in mice that were injected with transformed B. longum carrying the spectinomycin-resistant gene, the same number of bacilli was detected compared with the PBS control group (P ϭ .81).
Spectinomycin-resistant gene delivery into the hypoxic tumors
DISCUSSION
A central problem for cancer gene therapy is the lack of specificity of current delivery systems. After i.v. inocula- tion of B. longum to tumor-bearing mice, we initially observed a distribution of viable bacilli throughout the body; however, after 96 -168 hours, they were detectable only in the tumor tissue. The fact that the bacilli are not only detected but can also proliferate in the tumor tissue implies that this tissue possesses an environment that is suitable for the growth of this bacterium. The only requirement for the success of this gene therapy strategy in the clinic should be the presence of hypoxia in the treated tumors. Metastasized or disseminated lesions as well as primary disease should be amenable to the treatment as long as regions of hypoxia are present. Thus, the detection of a primary tumor locus or of a metastatic focus may be diagnostically feasible with the transformation of a suitable marker gene.
This gene delivery system is not only tumor-specific but also nontoxic. Some investigators have examined the availability of anaerobic bacteria such as Clostridia 16 -18 or Salmonella 19, 20 as gene delivery vectors, but the pathogenicity of these organisms in humans likely precludes their use. Some reports have demonstrated febrile adverse reactions as side effects after injection with Clostridium butyricum spores 21 or oral intake of Salmonella typhi. 22, 23 Conversely, Bifidobacterium strains are widely used for the preparation of fermented milk products in many Asiatic and Western countries. In addition to the assumed health-promoting properties of some Bifidobacterium species for humans, the nonpathogenicity of these microorganisms is now generally accepted. To be able to exploit the potential of these organisms for cancer gene therapy, detailed knowledge is required about such basic biological phenomena as cellular metabolism, gene expression, and protein secretion and genetics. However, studies on Bifidobacterium at the molecular level are severely limited in the absence of an efficient transformation system. Recently, Argnani et al 24 developed a system for the convenient and reproducible genetic transformation of strains of the genus Bifidobacterium. We demonstrated the tumorspecific germination of Bifidobacteria with transfected B. longum 105-A. The vector pBLES100 has two unique restriction sites, EcoRI and HindIII, which are suitable for gene cloning. These results strongly suggest that B. longum can be used as a highly specific gene delivery vector for cancer therapy. In the present study, spectinomycin-resistant gene, which is carried in pBLES100, functions in vivo, as shown in Figure 5 ; this finding indicates that any genes cloned in pBLES100, which is advantageous in the treatment of cancer, could be translated in B. longum specifically delivered to tumor tissues.
As a further safeguard for this gene delivery system, Bifidobacterium can be killed easily by antibiotics. We confirmed that both wt and genetically engineered B. longum were killed with 50 g/mL ampicillin in vitro (data not shown).
In summary, we have demonstrated that the genus Bifidobacterium, which is beneficial rather than nonpathogenic for its host, can be engineered. When these genetically engineered Bifidobacteria were introduced systemically into tumor-bearing mice, bacteria were found only in the tumors, presumably due to the hypoxic environment required for the growth of these bacteria. We believe that this novel approach for tumor targeting using Bifidobacteria could be useful for gene therapy of solid tumors.
